M&T Bank Corp Liquidia Corp Transaction History

M&T Bank Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$2.6 - $5.79 $71,409 - $159,022	-27,465 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$4.34 - $8.28 $26,391 - $50,350	6,081 Added 28.44%	27,465 $135,000
Q2 2020 Jul 29, 2020	BUY	$4.86 - $11.44 $23,123 - $54,431	4,758 Added 28.62%	21,384 $180,000
Q3 2019 Nov 12, 2019	BUY	$3.29 - $8.24 $8,310 - $20,814	2,526 Added 17.91%	16,626 $59,000
Q1 2019 May 15, 2019	BUY	$10.82 - $21.79 $152,562 - $307,239	14,100 New	14,100 $160,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.